Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel noncanonical Src-mammalian STE20-like kinase 1 (MST1)-Akt/glycogen synthase kinase-3β (GSK3β) pathway drives platelet activation and thrombosis.

Journal of thrombosis and haemostasis : JTH·2026
Same author

2025 White Paper on Recent Issues in Bioanalysis: Biomarkers Calibrators & Stability; Evaluation of NULISA; Neurofilament & Autoantibody Biomarker Assays; Removing IgM Interference; ELISpot & FluoroSpot Best Practices; Modular HD Cytometry; Single-cell Analysis Imaging Cytometry (PART 2A - Recommendations on Biomarkers Discovery, Development, Validation & Regulatory Approval, Ligand-Binding Assays (LBA) and Cell-Based Assays (CBA) PART 2B - Regulatory Agencies' Input on Biomarkers, IVD/CDx and Biomarker Assay Validation (BAV)).

Bioanalysis·2026
Same author

Transcription factor RUNX1 regulates coagulation factor XIII-A (<i>F13A1</i>): decreased platelet-megakaryocyte <i>F13A1</i> expression and clot contraction in <i>RUNX1</i> haplodeficiency.

Research and practice in thrombosis and haemostasis·2025
Same author

Transcription Factor RUNX1 Regulates Coagulation Factor XIII-A ( <i>F13A1</i> ): Decreased Platelet-Megakaryocyte <i>F13A1</i> Expression and Clot Contraction in <i>RUNX1</i> Haplodeficiency.

medRxiv : the preprint server for health sciences·2025
Same author

Phosphatidylserine-blocking nanoparticles inhibit thrombosis without increased bleeding in mice.

Journal of thrombosis and haemostasis : JTH·2024
Same author

Distinct Role of GRK3 in Platelet Activation by Desensitization of G Protein-Coupled Receptors.

Thrombosis and haemostasis·2024

Related Experiment Video

Updated: Jun 11, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

P2Y(12) antagonists as antiplatelet agents - Recent developments.

Kamala Bhavaraju1, Azad Mayanglambam, A Koneti Rao

  • 1Temple University School of Medicine, Department of Physiology, Philadelphia, PA 19140, USA.

Current Opinion in Drug Discovery & Development
|July 3, 2010
PubMed
Summary

Novel P2Y12 antagonists offer improved antiplatelet therapy for cardiovascular conditions. This review covers new agents, their clinical uses, and limitations compared to clopidogrel.

More Related Videos

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Experiment Videos

Last Updated: Jun 11, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Antiplatelet therapy is vital for acute coronary syndromes, stable coronary disease, and percutaneous coronary intervention.
  • Aspirin and clopidogrel are common antiplatelet agents, targeting thromboxane A2 and the P2Y12 receptor, respectively.
  • The P2Y12 receptor is a key target for antiplatelet drugs due to its specific functions.

Purpose of the Study:

  • To review recent advancements in novel P2Y12 antagonists.
  • To discuss the clinical implications and limitations of these new agents.

Main Methods:

  • Literature review of recent studies on P2Y12 antagonists.
  • Analysis of pharmacological profiles and clinical outcomes.

Main Results:

  • Clopidogrel, an irreversible P2Y12 antagonist, exhibits delayed action and variability.
  • Novel P2Y12 antagonists are being developed to overcome clopidogrel's limitations.
  • These newer agents aim for superior pharmacological profiles.

Conclusions:

  • Novel P2Y12 antagonists represent a significant advancement in antiplatelet therapy.
  • Further research is needed to fully understand their clinical utility and limitations.
  • These agents hold promise for improved patient outcomes in cardiovascular disease management.